Jeremy Levin Warns of Fragile Future for US Biotech Leadership

Jeremy Levin, a veteran of the global pharmaceutical and biotechnology industry, argues that while the scientific potential of biotech has never been higher, the American leadership position in the sector is increasingly at risk. Despite groundbreaking innovations in gene therapy and mRNA technology, systemic issues such as regulatory volatility, shifting capital market priorities, and a hostile political narrative surrounding drug pricing threaten to destabilize the industry. Levin emphasizes that biotechnology is now a matter of national security, akin to a modern-day space race. He cautions that without a stable ecosystem that supports long-term R&D, venture investment, and consistent policy, the United States risks losing its competitive edge to international rivals. The future of global health innovation depends not just on breakthroughs in the lab, but on the ability of American institutions to protect the incentives that make such discoveries possible. The industry must move beyond short-term political posturing to secure its place as a cornerstone of national growth and global progress.